Nifty
:
16945.05
Sensex
:
57527.10
-131.85 (-0.77%)
-398.18 (-0.69%)
Nifty
Sensex
:
:
16945.05
57527.10
-131.85 (-0.77%)
-398.18 (-0.69%)

Glenmark Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

Rating :
62/99

BSE: 532296 | NSE: GLENMARK

NSE BSE
425.70
24-Mar-2023
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 433.05
  • 444.95
  • 423.95
  • 436.75
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1094792
  •  4721.84
  •  487.55
  •  348.50

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 12,010.49
  • 13.67
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 14,269.32
  • 0.59%
  • 1.22

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.65%
  • 1.26%
  • 16.72%
  • FII
  • DII
  • Others
  • 23.19%
  • 10.16%
  • 2.02%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.49
  • 6.28
  • 4.96

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.62
  • 7.51
  • 6.44

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 4.27
  • 3.22
  • 6.66

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.30
  • 14.71
  • 14.19

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.81
  • 2.08
  • 1.75

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 11.70
  • 8.65
  • 7.49

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 22
Dec 21
Var%
Sep 22
Sep 21
Var%
Jun 22
Jun 21
Var%
Mar 22
Mar 21
Var%
Net Sales
3,463.86
3,173.41
9.15%
3,375.25
3,147.45
7.24%
2,777.29
2,964.89
-6.33%
3,019.15
2,859.90
5.57%
Expenses
2,843.61
2,480.26
14.65%
2,753.69
2,557.28
7.68%
2,345.69
2,391.32
-1.91%
2,555.75
2,336.47
9.39%
EBITDA
620.24
693.15
-10.52%
621.56
590.17
5.32%
431.60
573.58
-24.75%
463.40
523.43
-11.47%
EBIDTM
17.91%
21.84%
18.42%
18.75%
15.54%
19.35%
15.35%
18.30%
Other Income
76.41
13.89
450.11%
97.43
-13.07
-
183.16
58.65
212.29%
107.20
8.49
1,162.66%
Interest
97.27
66.70
45.83%
83.07
68.95
20.48%
59.99
75.60
-20.65%
86.85
83.33
4.22%
Depreciation
162.28
118.93
36.45%
155.71
123.19
26.40%
146.75
113.07
29.79%
131.52
111.07
18.41%
PBT
471.00
343.04
37.30%
480.21
384.96
24.74%
408.01
443.55
-8.01%
269.69
337.51
-20.09%
Tax
180.23
103.29
74.49%
201.54
110.16
82.95%
196.91
137.03
43.70%
97.13
103.65
-6.29%
PAT
290.76
239.75
21.28%
278.67
274.81
1.40%
211.11
306.53
-31.13%
172.57
233.87
-26.21%
PATM
8.39%
7.55%
8.26%
8.73%
7.60%
10.34%
5.72%
8.18%
EPS
9.66
7.86
22.90%
9.23
9.13
1.10%
6.82
10.86
-37.20%
5.51
8.29
-33.53%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Net Sales
12,635.55
12,304.90
10,943.93
10,640.97
9,865.47
9,074.42
9,079.41
7,561.67
6,680.94
5,944.95
4,969.14
Net Sales Growth
4.03%
12.44%
2.85%
7.86%
8.72%
-0.05%
20.07%
13.18%
12.38%
19.64%
 
Cost Of Goods Sold
4,375.72
4,312.08
3,620.18
3,623.78
3,283.71
2,963.32
2,552.03
2,246.58
1,538.25
1,785.62
1,584.70
Gross Profit
8,259.83
7,992.82
7,323.75
7,017.18
6,581.76
6,111.10
6,527.39
5,315.09
5,142.69
4,159.33
3,384.44
GP Margin
65.37%
64.96%
66.92%
65.94%
66.72%
67.34%
71.89%
70.29%
76.98%
69.96%
68.11%
Total Expenditure
10,498.74
9,984.60
8,859.55
8,942.89
8,279.67
7,459.05
7,042.71
6,124.52
5,466.62
4,854.17
3,953.86
Power & Fuel Cost
-
200.64
164.67
173.69
165.25
137.47
127.02
120.47
109.11
93.50
80.13
% Of Sales
-
1.63%
1.50%
1.63%
1.68%
1.51%
1.40%
1.59%
1.63%
1.57%
1.61%
Employee Cost
-
2,447.42
2,343.71
2,254.78
2,056.07
1,871.84
1,640.81
1,378.19
1,212.61
1,026.15
782.95
% Of Sales
-
19.89%
21.42%
21.19%
20.84%
20.63%
18.07%
18.23%
18.15%
17.26%
15.76%
Manufacturing Exp.
-
784.62
638.74
669.50
725.16
648.59
546.75
956.59
1,323.66
336.59
272.53
% Of Sales
-
6.38%
5.84%
6.29%
7.35%
7.15%
6.02%
12.65%
19.81%
5.66%
5.48%
General & Admin Exp.
-
1,264.86
1,027.60
1,168.32
891.10
526.29
1,022.89
491.20
253.29
859.67
678.94
% Of Sales
-
10.28%
9.39%
10.98%
9.03%
5.80%
11.27%
6.50%
3.79%
14.46%
13.66%
Selling & Distn. Exp.
-
896.31
943.21
1,005.63
1,125.08
996.99
1,064.70
892.67
991.23
524.25
521.00
% Of Sales
-
7.28%
8.62%
9.45%
11.40%
10.99%
11.73%
11.81%
14.84%
8.82%
10.48%
Miscellaneous Exp.
-
78.68
121.44
47.19
33.29
314.55
88.52
38.82
38.48
228.40
521.00
% Of Sales
-
0.64%
1.11%
0.44%
0.34%
3.47%
0.97%
0.51%
0.58%
3.84%
0.68%
EBITDA
2,136.80
2,320.30
2,084.38
1,698.08
1,585.80
1,615.37
2,036.70
1,437.15
1,214.32
1,090.78
1,015.28
EBITDA Margin
16.91%
18.86%
19.05%
15.96%
16.07%
17.80%
22.43%
19.01%
18.18%
18.35%
20.43%
Other Income
464.20
166.67
50.22
159.60
208.14
91.40
37.37
20.00
6.88
11.48
10.75
Interest
327.18
298.10
353.11
377.32
334.58
285.57
237.32
178.88
190.15
188.59
160.01
Depreciation
596.26
486.71
443.55
417.17
325.90
301.88
264.37
234.28
300.41
216.79
127.01
PBT
1,628.91
1,702.16
1,337.93
1,063.20
1,133.45
1,119.33
1,572.38
1,043.98
730.63
696.88
739.00
Tax
675.81
447.60
412.39
320.11
375.64
315.46
382.68
300.94
334.07
151.27
110.72
Tax Rate
41.49%
31.06%
29.83%
29.20%
28.88%
28.18%
25.66%
28.83%
61.46%
21.71%
14.98%
PAT
953.11
941.65
970.04
775.97
924.98
803.78
1,108.80
743.23
209.54
542.27
620.03
PAT before Minority Interest
881.14
993.65
970.09
775.97
924.99
803.87
1,108.75
743.04
209.47
545.60
628.29
Minority Interest
-71.97
-52.00
-0.05
0.00
-0.01
-0.09
0.05
0.19
0.07
-3.33
-8.26
PAT Margin
7.54%
7.65%
8.86%
7.29%
9.38%
8.86%
12.21%
9.83%
3.14%
9.12%
12.48%
PAT Growth
-9.65%
-2.93%
25.01%
-16.11%
15.08%
-27.51%
49.19%
254.70%
-61.36%
-12.54%
 
EPS
33.77
33.37
34.37
27.50
32.78
28.48
39.29
26.34
7.43
19.22
21.97

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Shareholder's Funds
9,086.65
7,064.63
6,070.51
5,605.18
5,163.48
4,492.52
3,629.64
1,783.49
2,983.28
2,763.03
Share Capital
28.22
28.22
28.22
28.22
28.22
28.22
28.22
27.13
27.12
27.09
Total Reserves
9,042.13
7,014.78
6,028.59
5,566.35
5,124.75
4,462.86
3,599.98
1,756.36
2,956.16
2,735.94
Non-Current Liabilities
1,269.61
2,803.62
3,033.01
2,279.94
2,824.12
3,257.81
1,499.40
2,749.09
1,966.58
1,625.13
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
2,428.66
1,920.30
Unsecured Loans
2,571.74
3,888.82
4,042.99
3,573.75
4,141.78
4,536.34
2,487.30
2,574.38
0.00
0.00
Long Term Provisions
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Liabilities
4,689.43
4,201.02
4,125.98
4,021.09
3,287.89
2,702.68
3,999.25
3,776.71
2,949.17
2,201.39
Trade Payables
2,288.66
2,237.77
2,125.84
2,220.75
1,869.78
1,743.22
1,940.79
1,948.04
1,362.58
1,036.94
Other Current Liabilities
1,446.27
885.78
1,001.63
1,013.21
690.60
509.32
1,137.01
1,264.30
973.31
763.41
Short Term Borrowings
370.00
513.01
442.60
303.02
295.04
187.19
787.42
347.60
353.32
367.82
Short Term Provisions
584.50
564.45
555.91
484.11
432.46
262.95
134.03
216.78
259.95
33.22
Total Liabilities
15,397.16
14,068.92
13,229.11
11,905.83
11,275.12
10,452.59
9,127.99
8,309.10
7,912.31
6,613.91
Net Block
5,887.25
5,128.85
5,028.56
3,670.25
3,029.55
2,755.09
2,593.55
2,015.38
2,889.66
2,406.26
Gross Block
10,213.47
8,731.58
8,269.83
6,527.27
5,367.95
4,769.92
4,300.54
3,495.47
3,632.62
2,934.90
Accumulated Depreciation
4,326.23
3,602.73
3,241.28
2,857.01
2,338.39
2,014.83
1,706.99
1,480.09
742.96
528.63
Non Current Assets
7,114.82
6,709.33
6,425.49
5,209.02
4,286.43
3,577.96
3,223.69
2,978.04
3,149.61
2,887.10
Capital Work in Progress
1,009.87
1,381.67
1,221.89
1,398.94
1,121.87
708.11
542.79
477.13
206.24
422.31
Non Current Investment
49.62
24.63
24.59
29.66
14.66
15.69
17.20
17.12
0.00
0.00
Long Term Loans & Adv.
161.38
146.29
123.97
94.36
119.78
98.94
69.99
468.16
33.39
36.52
Other Non Current Assets
6.70
27.89
26.49
15.80
0.56
0.13
0.16
0.27
20.33
22.00
Current Assets
8,282.35
7,359.58
6,803.62
6,696.82
6,988.69
6,874.64
5,904.30
5,331.06
4,762.69
3,726.81
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
2,499.83
2,276.83
2,135.62
2,252.07
2,030.59
2,139.05
1,567.76
1,269.04
932.88
843.53
Sundry Debtors
3,101.14
2,572.05
2,408.96
2,194.59
2,331.81
2,404.32
2,492.65
2,511.76
2,156.34
1,640.05
Cash & Bank
1,411.52
1,139.16
1,111.24
937.76
1,234.69
1,057.66
857.12
775.88
800.67
607.31
Other Current Assets
1,269.87
671.05
603.30
765.22
1,391.61
1,273.61
986.77
774.38
872.81
635.91
Short Term Loans & Adv.
537.12
700.49
544.48
547.18
580.83
590.22
594.89
742.94
768.44
540.03
Net Current Assets
3,592.92
3,158.56
2,677.63
2,675.73
3,700.80
4,171.96
1,905.05
1,554.35
1,813.53
1,525.42
Total Assets
15,397.17
14,068.91
13,229.11
11,905.84
11,275.12
10,452.60
9,127.99
8,309.10
7,912.30
6,613.91

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Cash From Operating Activity
1,108.65
1,131.21
1,392.41
1,324.17
1,648.05
657.43
344.85
481.68
853.73
647.93
PBT
1,441.25
1,382.47
1,096.08
1,300.63
1,119.33
1,491.43
1,043.98
543.54
696.88
739.00
Adjustment
787.11
644.82
636.23
329.83
571.28
726.56
391.03
522.76
709.78
342.45
Changes in Working Capital
-561.26
-385.84
127.06
136.34
309.06
-861.51
-611.96
-266.82
-290.07
-268.49
Cash after chg. in Working capital
1,667.09
1,641.45
1,859.37
1,766.81
1,999.67
1,356.48
823.05
799.49
1,116.58
812.96
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-558.44
-510.24
-466.95
-442.63
-351.61
-699.05
-478.20
-317.81
-262.86
-165.03
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-333.28
-675.24
-783.52
-698.99
-1,013.34
-712.35
-880.17
-540.04
-368.10
-464.06
Net Fixed Assets
-155.36
-184.89
-248.78
455.14
-362.24
-256.09
-286.93
-1,354.84
-112.12
-178.05
Net Investments
-1,569.44
-2,276.02
-1,445.18
-56.07
-1,345.98
-8.28
-198.90
-250.28
-114.91
-211.06
Others
1,391.52
1,785.67
910.44
-1,098.06
694.88
-447.98
-394.34
1,065.08
-141.07
-74.95
Cash from Financing Activity
-520.49
-441.78
-444.66
-738.74
-468.50
543.15
698.60
199.22
-98.02
195.24
Net Cash Inflow / Outflow
254.88
14.20
164.23
-113.56
166.21
488.24
163.27
140.86
387.61
379.11
Opening Cash & Equivalents
1,138.10
1,110.28
936.28
1,233.36
1,056.36
857.12
763.74
794.80
605.18
320.08
Closing Cash & Equivalent
1,410.53
1,138.10
1,110.28
936.28
1,233.36
1,056.36
857.12
763.74
794.80
605.18

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Book Value (Rs.)
321.45
249.60
214.65
198.27
182.62
159.16
128.59
65.74
109.99
102.01
ROA
6.74%
7.11%
6.17%
7.98%
7.40%
11.33%
8.52%
2.58%
7.51%
10.40%
ROE
12.33%
14.81%
13.32%
17.21%
16.67%
27.31%
27.46%
8.79%
18.99%
24.33%
ROCE
14.19%
15.30%
14.04%
16.47%
14.77%
20.54%
18.53%
12.40%
15.04%
17.67%
Fixed Asset Turnover
2.94
2.97
1.44
1.66
1.80
2.03
1.96
1.90
1.83
1.79
Receivable days
37.24
36.01
78.95
83.73
94.95
97.29
119.39
125.97
115.37
104.99
Inventory Days
31.35
31.90
75.25
79.22
83.59
73.65
67.68
59.42
53.99
59.39
Payable days
191.57
219.98
98.44
97.43
96.28
101.59
117.03
95.22
83.15
68.48
Cash Conversion Cycle
-122.98
-152.06
55.77
65.53
82.26
69.35
70.04
90.17
86.21
95.91
Total Debt/Equity
0.40
0.67
0.80
0.80
0.90
1.05
1.10
2.13
1.10
1.00
Interest Cover
5.83
4.92
3.90
4.89
4.92
7.28
6.84
3.86
4.70
5.62

Annual Reports:

FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013

News Update:


  • Glenmark Pharmaceuticals gets USFDA’s approval for Calcipotriene and Betamethasone Dipropionate Foam
    23rd Mar 2023, 09:18 AM

    With this approval, Glenmark is eligible for 180-days of generic drug exclusivity for Calcipotriene and Betamethasone Dipropionate Foam

    Read More
  • Glenmark Pharmaceuticals gets USFDA’s approval for Prochlorperazine Maleate Tablets
    20th Mar 2023, 09:19 AM

    Glenmark’s Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg, will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA

    Read More
  • Glenmark Pharmaceuticals’ arm gets USFDA’s approval for GRC 54276
    16th Mar 2023, 16:51 PM

    GRC 54276 is an orally available, small molecule hematopoietic progenitor kinase 1 (HPK1) inhibitor developed by Glenmark

    Read More
  • Glenmark Pharmaceuticals gets USFDA’s final nod for Clindamycin Hydrochloride Capsules
    14th Mar 2023, 11:39 AM

    Glenmark’s Clindamycin Hydrochloride Capsules USP, 75 mg, 150 mg, and 300 mg, will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA

    Read More
  • Glenmark Pharmaceuticals inks pact with Cediprof
    9th Mar 2023, 10:40 AM

    Glenmark expects to commence distribution of the product in the U.S. during the second half of 2023

    Read More
  • Glenmark Pharmaceuticals’ arm gets second tentative approval for Saxagliptin Tablets
    17th Feb 2023, 09:42 AM

    Glenmark’s first tentative approval letter for Saxagliptin Tablets, 2.5 mg and 5 mg was received on June 12, 2017

    Read More
  • Glenmark Pharmaceuticals reports 21% rise in Q3 consolidated net profit
    13th Feb 2023, 11:52 AM

    Total consolidated income of the company increased by 11.07% to Rs 3540.27 crore for Q3FY23

    Read More
  • Glenmark Pharma - Quarterly Results
    10th Feb 2023, 19:47 PM

    Read More
  • Glenmark Pharmaceuticals launches AKYNZEO I.V in India
    23rd Jan 2023, 09:18 AM

    The drug is already being marketed in the EU, the US, and Australia

    Read More
  • Glenmark Pharmaceuticals enters into agreement with Eris Oaknet Healthcare
    17th Jan 2023, 18:06 PM

    The divested Tail Brands include Onabet, Halovate, Sorvate, Luligee, Demelan, Aceret, Dosetil, Revize, and Powercort, and their sub-brands

    Read More
  • Glenmark Pharmaceuticals launches sacubitril + valsartan tablets in India
    17th Jan 2023, 14:22 PM

    The sacubitril-valsartan combination belongs to the class ARNI

    Read More
  • Glenmark Pharma’s arm launches Bumetanide Injection
    10th Jan 2023, 09:19 AM

    Glenmark’s current portfolio consists of 179 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the U.S. FDA

    Read More
  • Glenmark Pharmaceuticals launches first triple FDC Teneligliptin with Pioglitazone and Metformin
    21st Dec 2022, 09:24 AM

    This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation

    Read More
  • Glenmark Pharmaceuticals gets final nod for Nicardipine Hydrochloride Capsules from USFDA
    19th Dec 2022, 09:22 AM

    Glenmark’s Nicardipine Hydrochloride Capsules, 20 mg and 30 mg, will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA

    Read More
  • Glenmark Pharmaceuticals to divest cardiac brand ‘Razel’
    15th Dec 2022, 10:29 AM

    This divestment is in line with Glenmark’s strategy of focusing on other sub-categories of the cardio-vascular segment

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.